SEER — Seer Inc
NASDAQ · Healthcare · Biotechnology
$1.97
+$0.03 (+1.55%)
Seer Inc (SEER) is a biotechnology company listed on NASDAQ. It is led by Omid C. Farokhzad M.D., Ph.D., based in 3800 Bridge Parkway, Redwood City, CA, United States, 94065, with about 124 employees. Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest reported SEER revenue for 2025-09-30 was $4.1M. Net income was -$18.2M. Revenue was up 1.7% from 2025-06-30 to 2025-09-30. SEER currently screens at market cap $94.6M.
Use this SEER page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SEER quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SEER SEC filings page. Lician reads the product cache first so this HTML stays unique to Seer Inc even when a live quote feed is slow.
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
SEER Key Statistics
Market Cap
$94.57M
Volume
95,906
Previous Close
$2.04
Day Range
$2.03 – $2.08
P/B Ratio
0.39
EPS
$0.00
Revenue
$14.17M
Net Income
-$86.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-15.0%
Profit Margin
-611.1%
Employees
124
SEER Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $14.17M | $16.66M | $15.49M | $6.62M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$86.60M | -$86.28M | -$92.97M | -$71.17M |
| EPS (Diluted) | $0.00 | -$1.35 | -$1.49 | -$1.17 |
Total Assets
$366.60M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$40.75M
Operating Cash Flow
-$46.11M
Free Cash Flow
$0.00
Seer Inc Company Information
- Founder, CEO, & Chair of the Board of Directors
- Omid C. Farokhzad M.D., Ph.D.
- Headquarters
- 3800 Bridge Parkway, Redwood City, CA, United States, 94065
- Website
- seer.bio
- Phone
- 650 453 0000
- IPO / Founded
- 2020-12-04
- Sector
- Healthcare
- Industry
- Biotechnology